Canada: Shareholder Support Of Poison Pill Allows Target Board To "Just Say Slow" To Hostile Bid

The British Columbia Securities Commission (BCSC) recently released reasons for its May 5, 2014 order allowing Augusta Resource Corporation to keep its shareholder rights plan (also known as a poison pill) in place for an extended period—155 days after HudBay Minerals Inc. commenced its hostile bid. The Augusta decision confirms the importance of a shareholder vote on the continuation of a poison pill in the face of an unsolicited takeover bid. Shareholder support for a pill in the face of a hostile bid allows a target board to "just say slow".

The Augusta decision is the first significant poison pill case since the Canadian Securities Administrators (CSA) and Québec's securities regulator (AMF) announced competing proposals on changing how poison pills are regulated (see our bulletin, Canadian Companies Will Be Harder to Acquire Under New Poison Pill Proposals). Although the BCSC said that it did not apply the policy changes included in these proposals, the Augusta decision is consistent, in part, with the proposed CSA rules that place an increased emphasis on shareholder voting.

The status of the CSA and AMF proposals remains unknown, leaving provincial securities commissions to continue to regulate poison pills on a case-by-case basis. However, the Augusta decision indicates progress toward a more harmonized approach to the treatment of poison pills by provincial securities commissions; the decision is consistent with earlier poison pill cases in which securities commissions in Ontario and Alberta, in determining how long a poison pill should be allowed to stand, attached significant weight to shareholder approval of a poison pill.

Background: The Bid for Augusta

HudBay had initially attempted a negotiated transaction with Augusta and failed. HudBay announced in April 2013 that it had accumulated a 15% position in Augusta shares, prompting Augusta's board to adopt a poison pill. The pill was approved by Augusta shareholders in October 2013.

On February 10, 2014, HudBay commenced its bid, and then later sought to have Augusta's poison pill cease-traded by the BCSC. Augusta called a meeting of shareholders at which the poison pill was again put to shareholders for approval. Both the second shareholders meeting and the conclusion of the BCSC's poison pill hearing occurred on May 2, 2014. By that time, it had been 81 days since HudBay had commenced its takeover bid—significantly longer than the average time that securities commissions had previously allowed poison pills to remain in place. The evidence at the pill hearing showed that despite the time that Augusta's board had to use the pill, there was no real and substantial possibility that Augusta would find a superior transaction to HudBay's bid.

At the shareholders meeting, of the shares voted (78%), and excluding the shares held by HudBay and directors and officers of Augusta, over 90% were voted in favour of the continuation of the pill.

On May 5, 2014, the BCSC made its order allowing the pill to remain in place until July 15, 2014. On June 23, 2014, HudBay and Augusta announced a friendly transaction. The BCSC subsequently released its reasons.

The BCSC Decision

The BCSC ordered that Augusta's poison pill could stay in place until July 15, 2014, provided that HudBay extended its bid to July 16, 2014 and agreed to a further 10-day extension if HudBay took up any shares on that date. As a result of the order, the pill was allowed to remain in place for 155 days from the commencement of HudBay's bid, more than double the 60-day permitted bid period and well in excess of the average time of 45 - 60 days that securities commissions had previously allowed pills to remain in place. The time that Augusta's board was given to use the pill is particularly surprising in light of the fact that the BCSC concluded that it was unlikely that the board would be able to identify a better transaction. Under the earlier jurisprudence of the BCSC, and applying the well-known test for cease-trading poison pills, HudBay could reasonably have expected that the BCSC would have found that it was "time for the pill to go" (see Canadian Securities Regulators' Decisions on Poison Pills Diverge).

The BCSC stated in its reasons for allowing the continuation of Augusta's pill that it was mindful of, but did not apply, the CSA and AMF proposals. Under the CSA proposal, a poison pill can be adopted by a target board and remain effective as a defensive measure as long as it has been approved by disinterested shareholders. In the Augusta decision, the BCSC stated that it was not prepared to conclude that shareholder approval should be definitive with respect to the continuation of a poison pill. Making a shareholder vote definitive in the regulation of poison pills would not, according to the BCSC, strike the right balance between the interests of the majority of shareholders, who vote to continue a pill, and the rights of all shareholders to have the opportunity to tender to a bid. While a shareholder vote will be a very significant factor in favour of continuing a poison pill, the BCSC stated it would be contrary to the current national policy governing defensive measures to make that factor determinative.

The BCSC raised additional concerns about an approach to regulating pills that would make a shareholder vote determinative, including concerns about the shareholder voting system in Canada generally, which is currently under review (see our bulletin, Review of Canada's Proxy Voting System). In this case, the vote on Augusta's pill occurred in the face of HudBay's offer. The vote was informed and was overwhelmingly in favour of the pill, even taking into account trading that occurred before the shareholders meeting. The strength of the shareholder vote was the factor that ultimately drove the BCSC to allow Augusta's poison pill to remain in place for additional time. Of particular significance to the BCSC was that the numbers were so high that the votes by disinterested shareholders in favour of continuation of the pill represented an absolute majority of the Augusta shares, even assuming that every share that was not voted at the meeting would have been voted against the pill's continuation. The importance of this finding is consistent with the AMF proposal which requires a bid to include an irrevocable minimum tender condition that more than 50% of the target's shares held by independent shareholders must be tendered to the bid.

Implications

The Augusta decision shows an alignment by the BCSC with the earlier decisions in Neo Materials and Pulse Data, where the Ontario and Alberta securities commissions placed significant weight on shareholder ratification of a target board's adoption of a poison pill. It also reflects an extension of the OSC's decision in MOSAID where the shareholder vote to renew a poison pill during a hostile bid gave the target board an additional 70 days after the commencement of the bid to pursue strategic alternatives.

The Augusta decision reinforces the significance of a shareholder vote approving a target board's adoption of a poison pill in the face of a hostile bid as a shield to give a target board more time to pursue strategic alternatives. To the extent that seeking shareholder ratification of a poison pill becomes a part of a target board's strategy in response to a hostile bid, we may see shareholder meetings becoming an increased focus for disputes before the regulators and the courts.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.